800 Scudders Mill Rd
Tel: (609) 987-5800
About Novo Nordisk
Novo Nordisk is the world's leading diabetes care company and the only company that provides a complete portfolio of insulin analog treatments and insulin delivery devices that respond to each stage of the diabetes life cycle. In addition, Novo Nordisk has a leading position in hemostasis management, growth hormone therapy and hormone therapy for women.
Novo Nordisk's ambition is to defeat diabetes, working as a catalyst to advance diabetes care through awareness, prevention, and education and to be at the forefront of research and development in other areas of healthcare where it can make a significant difference.
Triple Bottom Line
Novo Nordisk conducts its activities in a financially, environmentally, and socially responsible way as part of its underlying business principle, The Triple Bottom Line. This principle is the foundation of the Novo Nordisk Way of Management, which holds Novo Nordisk to the highest performance standards.
Novo Nordisk Highlights
• A heritage in diabetes care for more than 80 years • World's largest makers of insulin • More than 4,600 employees are engaged in research and development • In 2005, spent DKK 5,085 million in R & D • Operates manufacturing facilities in six nations, including the United States • Operates three research and development facilities worldwide (Denmark, US, China) • Rated as a healthcare leader on the global Dow Jones Sustainability World Index as well as the pan-European Dow Jones STOXX Sustainability Index (global recognition) • Named number one best place to work among large companies in NJ by NJBIZ magazine
• Global headquarters in Copenhagen, Denmark • US headquarters in Princeton, NJ • Employs an estimated 27,000 people in 81 countries • Markets its products in 179 countries • Employs 3900 people in the US • Insulin manufacturing facility in Clayton, NC
Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'.
Total sales in 2008 were: $8,935 million (DKK 45,553m) Net income-as reported in 2008: $1,892 million (DKK 9,645m) Earnings per share-as reported: $3.07(DKK 15.66) Dividends paid per share: $1.18(DKK 6.00)
History of Novo Nordisk
In the 1920s, two small Danish companies began producing insulin, which had just been discovered by a team of Canadian scientists. Nordisk Insulin laboratorium was founded in 1923.
A year later, Novo Terapeutisk Laboratorium was born, and began producing "Insulin Novo" and a special syringe. Over the decades, these two companies grew to be global leaders in insulin production. In January 1989, Novo and Nordisk decided to join forces to form a new company called Novo Nordisk A/S.
Please click here for clinical trial information.
FOLLOW NOVO NORDISK:
Tweets by Novo Nordisk
1059 articles with Novo Nordisk
In October, the Minnesota Attorney General filed a lawsuit against three of the biggest insulin manufacturers over price gouging claims. One month later the American Diabetes Association published recommendations and public policy solutions.
Novo Nordisk Investment Fund Backs Companies Developing Therapies Combatting Antimicrobial Resist...
1/21/2019Novo Nordisk’s investment arm, Novo Holdings, invested a little more than $20 million in four different companies over the course of 2018 through its REPAIR Impact Fund. That $165 million fund was established last year to support companies developing therapies to combat antimicrobial resistance.
It didn’t take long for the new leadership structure in the U.S. House of Representatives to take on the pharmaceutical industry. On Monday, the House Committee on Oversight and Reform launched an investigation into prescription drug pricing practices.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia
Forbion today announces that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia.
BioGeneration Ventures' portfolio company Staten Biotechnology announces collaboration with Novo Nordisk
BioGeneration Ventures is pleased to announce that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement.
Indianapolis-based Eli Lilly announced that its diabetes drug Trulicity (dulaglutide) reduced major adverse cardiovascular events (MACE) in its REWIND clinical trial.
Novo Seeds incubatee Embark Biotech enters collaboration with Novo Nordisk to discover novel therapeutics for obesity and metabolic disease
Embark was first incubated by Novo Seeds and funded through the pre-seed grant programme of the Novo Nordisk Foundation in 2016
NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NAS...
Novo Seeds invests €12.5 million becoming largest shareholder
Companies to Develop Digital Health Solutions to Improve Diabetes Care
10/22/2018Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes.
Anthem, HealthCore and Novo Nordisk Launch Large, Real-World Pragmatic Study to Understand the Effectiveness of a New Type 2 Diabetes Drug
Real-world study compares Ozempic® (semaglutide) to other standard diabetes therapies
10/17/2018The Minnesota Attorney General is calling out Sanofi-Aventis, Novo Nordisk and Eli Lilly over alleged price gouging for insulin. This week Minnesota Attorney General Lori Swanson filed a lawsuit against the three companies over insulin price hikes.
New phase 2 data for somapacitan demonstrate its potential as an efficacious once-weekly treatment for childhood growth hormone deficiency
Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin® (somatropin) in a phase 2 trial in children with growth hormone deficiency.
Earlier this month, Novo Nordisk announced it was laying off 400 staffers in Denmark and China. Today, Reuters reports that the Danish company plans to lay off about 250 people in the United States.
Eli Lilly just signed a license deal with Tokyo’s Chugai Pharmaceutical Co. for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. It is Phase 1-ready being evaluated for type 2 diabetes.
Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalcoholic steatohepatitis, also known as NASH.
AstraZeneca announced positive results from its Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).
9/19/2018Days after selling future royalty streams for two Sanofi diabetes drugs for $205 million, Denmark-based Zealand Pharma announced its Phase III trial for severe insulin-induced hypoglycemia in diabetes hit all primary and key secondary endpoints that sets up potential regulatory approval.